Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Verrica Pharmaceuticals Inc (NASDAQ: VRCA) closed at $1.31 down -9.66% from its previous closing price of $1.45. In other words, the price has decreased by -$9.66 from its previous closing price. On the day, 1.73 million shares were traded. VRCA stock price reached its highest trading level at $1.5395 during the session, while it also had its lowest trading level at $1.31.
Ratios:
For a deeper understanding of Verrica Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.23 and its Current Ratio is at 2.36.
On March 22, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $10.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on February 13, 2023, whereas the target price for the stock was revised from $4 to $11.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 26 ’24 when Hayes Christopher G. sold 26,183 shares for $2.66 per share. The transaction valued at 69,647 led to the insider holds 115,303 shares of the business.
Hayes Christopher G. sold 9,530 shares of VRCA for $23,444 on Aug 27 ’24. The CHIEF LEGAL OFFICER now owns 105,773 shares after completing the transaction at $2.46 per share. On Aug 26 ’24, another insider, Goldenberg Gary, who serves as the Chief Medical Officer of the company, sold 9,888 shares for $2.66 each. As a result, the insider received 26,302 and left with 97,862 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRCA now has a Market Capitalization of 55895864 and an Enterprise Value of 70275808. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.02. Its current Enterprise Value per Revenue stands at 5.053 whereas that against EBITDA is -0.907.
Stock Price History:
Over the past 52 weeks, VRCA has reached a high of $11.41, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -59.06%, while the 200-Day Moving Average is calculated to be -77.63%.
Shares Statistics:
For the past three months, VRCA has traded an average of 902.75K shares per day and 1850050 over the past ten days. A total of 42.41M shares are outstanding, with a floating share count of 26.07M. Insiders hold about 38.89% of the company’s shares, while institutions hold 43.81% stake in the company. Shares short for VRCA as of 1726185600 were 3252865 with a Short Ratio of 3.60, compared to 1723680000 on 4189088. Therefore, it implies a Short% of Shares Outstanding of 3252865 and a Short% of Float of 17.119999999999997.
Earnings Estimates
Verrica Pharmaceuticals Inc (VRCA) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.24 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.36 and -$1.44 for the fiscal current year, implying an average EPS of -$1.4. EPS for the following year is -$0.85, with 3.0 analysts recommending between -$0.75 and -$0.98.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $5.54M this quarter.It ranges from a high estimate of $7.11M to a low estimate of $3.2M. As of the current estimate, Verrica Pharmaceuticals Inc’s year-ago sales were $510kFor the next quarter, 4 analysts are estimating revenue of $6.9M. There is a high estimate of $9.07M for the next quarter, whereas the lowest estimate is $4.3M.
A total of 4 analysts have provided revenue estimates for VRCA’s current fiscal year. The highest revenue estimate was $25.14M, while the lowest revenue estimate was $16.6M, resulting in an average revenue estimate of $21.46M. In the same quarter a year ago, actual revenue was $5.12MBased on 4 analysts’ estimates, the company’s revenue will be $51.67M in the next fiscal year. The high estimate is $70M and the low estimate is $23.1M.
